Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Mehmet Asim Bilen"'
Autor:
David R. Shaffer, Matthew H. Taylor, Alvaro Pinto, Daniel Heinrich, Chung-Han Lee, Chinyere E. Okpara, Øyvind Krohn Tennøe, Mehmet Asim Bilen, Donald A. Richards, Jane Wu, Randy F. Sweis, Arpit Rao, Rodolfo F. Perini, Amishi Yogesh Shah, Allen Lee Cohn, Jay Courtright, James J. Hsieh, Emmett V. Schmidt, Sara Gunnestad Ribe, Alan D. Smith, Drew W. Rasco, Robert J. Motzer, Regina Gironés Sarrió, Christopher Di Simone, Sharad Jain, Musaberk Goksel, Peter Kubiak, Nicholas J. Vogelzang
Publikováno v:
LANCET ONCOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Summary Background Despite advances in the first-line treatment of metastatic renal cell carcinoma (RCC), there is an unmet need for options to address disease progression during or after treatment with immune checkpoint inhibitors (ICIs). Pembrolizu
Autor:
Wanling Xie, Sumanta K. Pal, Daniel M. Geynisman, Elizabeth R. Plimack, Nieves Martinez Chanza, Jarred Burkart, Yousef Zakharia, Sumit A. Shah, Hannah Dzimitrowicz, Saby George, Mehmet Asim Bilen, Naomi B. Haas, Russell K. Pachynski, Walter M. Stadler, Dominick Bossé, I. Alex Bowman, Abhishek Tripathi, Lauren C. Harshman, Toni K. Choueiri, Nicholas J. Vogelzang, Sandy Srinivas, Andrew W. Hahn, Rana R. McKay, Anthony Mega, Benoit Beuselinck, Jo Ann Hsu, Vivek Narayan, Ulka N. Vaishampayan, Rohit Jain, Michael R. Harrison, Daniel Y.C. Heng, Neeraj Agarwal, Archana Balakrishnan, Benedito A. Carneiro, Amir Mortazavi, Hans J. Hammers, Elaine T. Lam, Tracy L. Rose
Publikováno v:
The Lancet Oncology. 20:581-590
Summary Background Cabozantinib is approved for patients with metastatic renal cell carcinoma on the basis of studies done in clear-cell histology. The activity of cabozantinib in patients with non-clear-cell renal cell carcinoma is poorly characteri